BML-111, the agonist of lipoxin A4, suppresses epithelial-mesenchymal transition and migration of MCF-7 cells < em > via < /em > regulating the lipoxygenase pathway

Conclusion: Our results suggest that BML-111 may be a potential therapeutic drug for breast cancer and that blocking the 5-LOX pathway could be a possible approach for mining effective drug targets.PMID:38134963 | PMC:PMC10748613 | DOI:10.1177/03946320231223826
Source: International Journal of Immunopathology and Pharmacology - Category: Allergy & Immunology Authors: Source Type: research